Grant Award Details
A phase 1 trial of LADICell, autologous beta 2 integrin transduced hematapoeitic stem cells, for severe Leukocyte Adheision Deficiency-1
Grant Application Details
Therapeutic Candidate or Device
The therapeutic candidate is an ex-vivo autologous gene therapy approach for Leukocyte Adhesion Deficiency-I (LAD-I).
The target clinical indication is Leukocyte Adhesion Deficiency-I (LAD-I), a pediatric hematological rare disease.
The therapeutic is based in an ex-vivo, lentiviral-based, patient-specific approach by genetically engineering the patient's own CD34 positively selected cells with the corrected genetic sequence of ITGB2 (aka LAD-I) gene and subsequently infusing the corrected cells to deliver a potential cure.
Unmet Medical Need
Children with severe LAD-I present with recurrent, life-threatening infections resulting in ~60-75% mortality prior to reaching the age of 2 years in the absence of a successful allogeneic HSCT (due to extensive bacterial or fungal infection). LADICell will treat the underlying gene defect.
Phase 2 trial completed
Major Proposed Activities
- Patient recruitment, screening, and support (by various CMOs) on their clinical journey
- Enrollment of patients at UCLA
- Cell processing in California
Cell processing activities in California provides jobs and an opportunity to be at the forefront of gene therapy to Californian workers. Clinical studies at UCLA Mattel Children's Hospital will further provide that medical and scientific community premier access to a cutting-edge gene therapy trial.